To advance clinical and non-clinical development of an antibiotic candidate.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00022
- Awardee
-
Spero Therapeutics, Inc. UEI NX34PL7NZW24
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,501,521
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- 2020 NIAID Omnibus Broad Agency Announcement Award Notice · Posted May 12, 2021
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 39% obligated
-
- $10,501,521.27 Current, with exercised options
- $27,032,719.27 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 23 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cambridge, MA 02139, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Terminate for Convenience | $0 | |
| Funding Only Action | $3,424,537 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $85,208 | |
| Exercise an Option | $779,592 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $149,482 | |
| Exercise an Option | $3,972,923 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,089,779 |
Show all 15
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Spero Therapeutics, Inc. on May 17, 2021, to advance clinical and non-clinical development of an antibiotic candidate, with a ceiling value of $27,032,719.27.
The contract carries no set-aside and is priced on a cost-plus-fixed-fee basis. Place of performance is Cambridge, MA. The originating pre-solicitation, posted December 11, 2019, sought proposals to support research and development efforts for advanced therapeutic candidates and medical countermeasures targeting infectious diseases including antibiotic-resistant bacteria, with a maximum performance period of five years. Ultimate completion date is April 4, 2025.
Service Contract Inventory reporting shows the contract has invoiced $5.2 million cumulatively through FY2025. Government-paid hourly rates rose significantly from $329.53 per hour in FY2021 to $2,731.39 per hour in FY2024, reflecting the shifting nature of work scope over the performance period. Most recent staffing (FY2025) was 0.1 FTEs with self-performed labor; no subcontractors were engaged.
Quick answers
Who was awarded contract 75N93021C00022?
75N93021C00022 was awarded to Spero Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 17, 2021.
How much is contract 75N93021C00022 worth?
The government has obligated $10,501,521 on 75N93021C00022. Its potential value, with all options, is $27,032,719.
Was contract 75N93021C00022 competed?
The extent of competition for 75N93021C00022 was full and open competition. The government received 23 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award